KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Invested Capital (2016 - 2025)

Regeneron Pharmaceuticals has reported Invested Capital over the past 17 years, most recently at $32.0 billion for Q4 2025.

  • Quarterly results put Invested Capital at $32.0 billion for Q4 2025, up 4.51% from a year ago — trailing twelve months through Dec 2025 was $32.0 billion (up 4.51% YoY), and the annual figure for FY2025 was $32.0 billion, up 4.51%.
  • Invested Capital for Q4 2025 was $32.0 billion at Regeneron Pharmaceuticals, up from $31.0 billion in the prior quarter.
  • Over the last five years, Invested Capital for REGN hit a ceiling of $32.0 billion in Q4 2025 and a floor of $12.7 billion in Q1 2021.
  • Median Invested Capital over the past 5 years was $24.5 billion (2023), compared with a mean of $24.7 billion.
  • Biggest five-year swings in Invested Capital: surged 77.75% in 2021 and later increased 4.51% in 2025.
  • Regeneron Pharmaceuticals' Invested Capital stood at $20.0 billion in 2021, then increased by 19.47% to $23.9 billion in 2022, then increased by 13.85% to $27.2 billion in 2023, then grew by 12.43% to $30.6 billion in 2024, then grew by 4.51% to $32.0 billion in 2025.
  • The last three reported values for Invested Capital were $32.0 billion (Q4 2025), $31.0 billion (Q3 2025), and $29.9 billion (Q2 2025) per Business Quant data.